ADC Therapeutics SA (ADCT)

Market Cap	501.75M
Revenue (ttm)	77.25M
Net Income (ttm)	-169.94M
Shares Out	112.50M
EPS (ttm)	-1.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	533,797
Open	4.610
Previous Close	4.630
Day's Range	4.350 - 4.670
52-Week Range	1.050 - 4.800
Beta	1.99
Analysts	Strong Buy
Price Target	7.60 (+70.4%)
Earnings Date	Nov 7, 2025

About ADCT

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines o...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 15, 2020
• Employees: 265
• Stock Exchange: NYSE
• Ticker Symbol: ADCT
• Website: https://www.adctherapeutics.com

Financial Performance

In 2024, ADC Therapeutics's revenue was $70.84 million, an increase of 1.84% compared to the previous year's $69.56 million. Losses were -$157.85 million, -34.25% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for ADCT stock is "Strong Buy." The 12-month stock price target is $7.6, which is an increase of 70.40% from the latest price.

Price Target

$7.6

(70.40% upside)

Analyst Consensus: Strong Buy